Latest ankylosing spondylitis Stories
On December 5th, 2014, “Broads for Bones with the Biggest D&*k in Hollywood!” will take place at Three Clubs Cocktail Lounge, 1123 N. Vine St. Hollywood CA 90038.
- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies EAST HANOVER, N.J., Nov.
- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 EAST HANOVER, N.J., Nov.
VANCOUVER, Nov. 5, 2014 /PRNewswire/ - Augurex Life Sciences Corp.
Ankylosing spondylitis is a systemic disease that causes inflammation in the spinal joints and was thought to have affected members of the ancient Egyptian royal families.
Arthritis Society says patient safety paramount as new class of medications become available Toronto, ON (PRWEB) September 18, 2014 With the arrival
VANCOUVER, May 29, 2014 /PRNewswire/ - Augurex Life Sciences Corp.
Arthritis advocates unite in State Capitol on April 22-23 to raise awareness and support for the disabling disease affecting more than 5.3 million Californians. SACRAMENTO, Calif.,
In May, over three dozen nonprofits around the world, along with thousands of patients, supporters, practitioners, and researchers, will unite under one ‘virtual roof’ to participate in the
- A gift; a largess; a gratuity; a present; a dole.